New Commercial Partnership in Mexico

About this update from Probiotix Health Plc

  10 October 2024     ProBiotix Health plc ("ProBiotix" or the "Company" or, together with its subsidiary, the "Group")   New Commercial Partnership in Mexico   ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, is pleased to announce a new commercial partnership with Mexico based raw materials and ingredients specialist Raff.   Founded in 1999, Raff is a distributor of raw materials and value-added ingredients, with a particular focus on the dairy and nutraceutical sectors. Backed by a highly trained technical team, Raff specialises in the use and application of lactic and probiotic cultures, rennet, enzymes and preservatives.   Mexico has a population of 131 million people, with cardiovascular disease the single largest killer, accounting for nearly 24% of all deaths. Moreover, it is estimated that around 3.6 million people die in Mexico every year from high cholesterol. The movement from 'cure' towards 'prevention' provides a strong backdrop for the fast-growing supplement market, which should lead to a good sales opportunity for ProBiotix.   The five-year agreement enables Raff to act in partnership with ProBiotix, as the exclusive distributor of LP LDL ®   to be used as an ingredient for the local manufacturing of finished products. The launch is planned for the first half of 2025, with commercial sales expected in late 2025/early 2026.   Steen Andersen, CEO of ProBiotix, commented : "After lengthy discussions we are delighted to announce our partnership with Raff and firmly believe that they share our ethos - to develop innovative products to help enrich individuals with healthier lives.   "The cardiovascular drug market in Mexico is estimated to be worth $2.2 billion this year, and provides a huge latent opportunity. With an ageing population, we believe Mexico provides a highly attractive market for ProBiotix to target."   Rafael Gonzalez, Commercial Director of Raff, added : "As an already well established probiotics supplier in the Mexican market through our relationship with Italy based Sacco Systems, having the opportunity to partner with ProBiotix Health, being a pioneer within probiotics and cardiometabolic health, is extremely exciting for us.   "We welcome the opportunity to expand our portfolio with a unique well documented precision biotic like LP LDL ® . It is our belief that LP LDL ®    fills an untapped potential in the fast growing Mexican supplement market, and that the product sits well with our already strong position in the sector."   For further information, please contact:     ProBiotix Health plc https://probiotixhealth-ir.com/ Steen Andersen, Chief Executive Officer Contact via Walbrook below Peterhouse Capital Limited ( Aquis Corporate Adviser and Broker)     Mark Anwyl   Tel: 020 7220 9793   Walbrook PR Ltd [email protected] Anna Dunphy Mob: 07876 741 001  

View stock analysis, news, and events for Probiotix Health Plc